CF
RPRX icon

Corebridge Financial’s Royalty Pharma RPRX Stock Holding History

Corebridge Financial’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,595
Closed -$80.8K – 2237
2025
Q1 		$80.8K Sell
2,595
-125
-5% -$3.96K ﹤0.01% 2547
2024
Q4 		$69.4K Sell
2,720
-194
-7% -$5.14K ﹤0.01% 2721
2024
Q3 		$82.4K Sell
2,914
-92
-3% -$2.55K ﹤0.01% 2704
2024
Q2 		$79.3K Buy
+3,006
New +$83.3K ﹤0.01% 2720

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CIA
Caledonia Investments (Australia) Sydney NSW, Australia $3.44B AUM 20.03% 1-Year Est. Return

Corebridge Financial's RPRX Position: Q2 2025 in Review

Corebridge Financial sold out of Royalty Pharma (RPRX) in Q2 2025, closing a stake of 2,595 shares — an estimated $80.8K sold.

Corebridge Financial first reported a position in RPRX in Q2 2024 and held it in 4 quarters. The position peaked at $82.4K in Q3 2024. 455 funds tracked by Wall St. Rank hold RPRX as of Q2 2025.

  • Corebridge Financial reported no remaining Royalty Pharma position as of Q2 2025 after selling out during the quarter.
  • Corebridge Financial sold 2,595 Royalty Pharma shares in Q2 2025, an estimated $80.8K.
  • Corebridge Financial first reported a position in Royalty Pharma in Q2 2024 and held it in 4 quarters.
  • Corebridge Financial's Royalty Pharma position peaked at $82.4K in Q3 2024.
  • 455 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.